These IPA and IAA administrations revealed the mechanism of anti-MASLD by inhibiting the NF-κB pathway through reduction of endotoxin levels and inactivation of macrophages. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.